Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure. Issue 4 (9th July 2021)

• Record Type: Journal Article
• Authors: Rothenberger, Rodger; Jones, Wendy; MacNeill, Colin
• Is Part Of: Sexual medicine. Volume 9:Issue 4(2021)
• Page Start: 100383
• Page End: 100383
• Publication Date: 2021-07-09
• Subjects: Vulvodynia -- Vulvovaginitis -- Itraconazole -- Fluconazole -- Azole -- Antifungal; Sexual disorders -- Periodicals; Sexual health -- Periodicals; 616.69005
• DOI: 10.1016/j.esxm.2021.100383
• Languages: English
• ISSNs: 2050-1161

Abstract

Abstract: Introduction: Vulvodynia is a difficult condition to treat due to both the uncertain etiology of the disorder and poorly available therapies. This difficulty leads to a disproportionately high prevalence and cost of treatment for this condition. Candida vulvovaginitis is a frequent co-present diagnosis in vulvodynia patients. Whether through treatment of co-present, candida vulvovaginitis or by systemic interaction, itraconazole has been proposed as a treatment for vulvodynia. Aim: To describe objective change in vulvodynia pain in a cohort of patients treated with itraconazole. Methods: This study was a retrospective cohort study comprised of women diagnosed with vulvodynia who were treated with itraconazole between January 1, 2011 and October 17, 2017. Patients had failed fluconazole treatment and had negative fungus cultures for >2 months before itraconazole treatment. All other vulvovaginal disorders were excluded. Main outcome measure: The main outcome measure was the change in pain before and after treatment as measured by cotton swab testing. Results: 106 patients met inclusion criteria. Average pain reduction for the entire cohort was 60.7%. Patients who continued itraconazole for 5 to 8 weeks demonstrated a 69.6% reduction in cotton swab test pain. Pain reduction as a percentage of total patients showed complete resolution of pain in 37.7% of patients and >50% reduction in 66.0% of patients. Two-sample paired T-tests for means analysis of pain scores disproved the null hypothesis ( P < .01, α = 0.01) and showed a 50% reduction in pain to be significant ( P = 0.043, α = 0.05). Two-tailed Wilcoxon signed rank test also demonstrated rejection of the null hypothesis (α = 0.05). Conclusions: Itraconazole therapy is associated with a significant reduction in vulvovaginal pain in patients with negative fungus cultures and no other identifiable disease in this pilot study. A randomized placebo-controlled trial is warranted.